Alexander Stepanov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexander Stepanov has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Evgeniy V. Ivchenko
Kirov Military Medical Academy
3 shared publications - Sergey Viktorovich Chepur
State research testing Institute of military medicine of the Ministry of defense of the Russian Federation
3 shared publications - Alebai U. Sabitov
Ural State Medical University
2 shared publications - Elena P. Tikhonova
Voino-Yasenetsky Krasnoyarsk State Medical University
2 shared publications - Elena Vladimirovna Esaulenko
Saint Petersburg State Pediatric Medical University
2 shared publications K. V. Zhdanov
S. M. Kirov Military Medical Academy of the Ministry of Defence of the Russian Federation
2 shared publications
Latest Publications
- 30 September 2025
- Published by ECO-Vector LLC (Publications) in Russian Military Medical Academy Reports
- Vol. 44 (3) , 323-330
Modern approaches to pertussis vaccination
Pertussis is an acute respiratory disease caused by Gram-negative bacteria Bordetella pertussis. Pertussis is highly contagious for all age groups; however, it primarily affects children under the age of one year. Despite decades of high vaccine coverage, pertussis has currently resurged, with a rising prevalence in adolescents and adults. This study aimed to assess possible causes of increased incidence of pertussis and the efficacy of existing strategies for preventing its resurgence and spreading. Furthermore, the work examined promising areas of pertussis immunoprophylaxis in the current setting. The study identified the main causes of increased incidence of pertussis and changes in the incidence pattern. These include insufficient efficacy of available immunobiologicals for pertussis prevention, rapid decline in acquired immunity (primarily due to incorrect vaccination schedule), increased prevalence of atypical forms of pertussis, and the emergence of new pathogen strains with higher resistance to existing vaccines. Improving specific pertussis immunoprophylaxis necessitates a broader vaccine coverage to include women in the third trimester of pregnancy, families with children (especially young ones), those who work with children, and healthcare professionals. Reimmunization in older individuals (65 years old) must be performed every 10 years. Furthermore, innovative pertussis vaccines are required. Molecular biology techniques and a thorough assessment of the disadvantages of existing vaccines are essential for developing new drugs that are effective against modified strains. Moreover, selecting and using vaccine adjuvants that activate both innate and acquired immunity is crucial for developing new vaccines. These strategies will provide more effective control over this vaccine-preventable disease and prevent its resurgence.
- 30 September 2025
- Published by ECO-Vector LLC (Publications) in Russian Military Medical Academy Reports
- Vol. 44 (3) , 323-330
Modern approaches to pertussis vaccination
Pertussis is an acute respiratory disease caused by Gram-negative bacteria Bordetella pertussis. Pertussis is highly contagious for all age groups; however, it primarily affects children under the age of one year. Despite decades of high vaccine coverage, pertussis has currently resurged, with a rising prevalence in adolescents and adults. This study aimed to assess possible causes of increased incidence of pertussis and the efficacy of existing strategies for preventing its resurgence and spreading. Furthermore, the work examined promising areas of pertussis immunoprophylaxis in the current setting. The study identified the main causes of increased incidence of pertussis and changes in the incidence pattern. These include insufficient efficacy of available immunobiologicals for pertussis prevention, rapid decline in acquired immunity (primarily due to incorrect vaccination schedule), increased prevalence of atypical forms of pertussis, and the emergence of new pathogen strains with higher resistance to existing vaccines. Improving specific pertussis immunoprophylaxis necessitates a broader vaccine coverage to include women in the third trimester of pregnancy, families with children (especially young ones), those who work with children, and healthcare professionals. Reimmunization in older individuals (65 years old) must be performed every 10 years. Furthermore, innovative pertussis vaccines are required. Molecular biology techniques and a thorough assessment of the disadvantages of existing vaccines are essential for developing new drugs that are effective against modified strains. Moreover, selecting and using vaccine adjuvants that activate both innate and acquired immunity is crucial for developing new vaccines. These strategies will provide more effective control over this vaccine-preventable disease and prevent its resurgence.
- Open Access
- 4 January 2023
- Published by ECO-Vector LLC in Bulletin of the Russian Military Medical Academy
- Vol. 24 (4) , 659-666
Dynamics of the content of immunoglobulin G to severe acute respiratory syndrome-2 in convalescents who have had a new coronavirus infection
The study investigated the dynamics of class G immunoglobulins to severe acute respiratory syndrome-2 coronavirus in the blood serum of convalescents who had a new coronavirus infection for 6 months after the polymerase chain reaction conversion. Among the most common symptoms, 30 (73.8%) convalescents had an increase in body temperature to 38C, 32 (83.3%) had asthenia, 21 (59.5%) had cough, 29 (73.8%) had perversion or loss of sense of smell, pain, and throat discomfort. The duration of symptoms varied from 34 days to 34 weeks. Within a month after the end of the acute disease period, 8 (20%) patients had a decrease in working capacity, 13 (33%) had difficulty breathing, 9 (22%) had a cough, and 4 (10%) had pain and sore throat. During severe acute respiratory syndrome 2 infection, the virus activates the innate and adaptive immunity, resulting in the formation of specific class G immunoglobulins to the pathogens. After leveling the clinical manifestations, class G immunoglobulins were detected in the majority of convalescents (79%90%) during the first 6 months, starting from day 14 from disease onset with a predominantly high ( 10 conl. units) positivity coefficient. Moreover, this pattern occurred in both men and women; however, in some studies, the levels of the positivity coefficient of class G immunoglobulins began to decrease by the fifth month of follow-up and sometimes at an earlier time (2 months). Perhaps, this is due to the different functional activities of the immune system of each convalescent, infecting dose of the pathogen, and peculiarities of its interaction with the macroorganism and its immune system. Nevertheless, the class G immunoglobulins identified in the study do not yet indicate the probability of reinfection of convalescents with the same pathogen. The protective titer of antibodies has yet to be investigated further.
- 4 January 2023
- Published by ECO-Vector LLC in Bulletin of the Russian Military Medical Academy
- Vol. 24 (4) , 659-666
Open AccessDynamics of the content of immunoglobulin G to severe acute respiratory syndrome-2 in convalescents who have had a new coronavirus infection
The study investigated the dynamics of class G immunoglobulins to severe acute respiratory syndrome-2 coronavirus in the blood serum of convalescents who had a new coronavirus infection for 6 months after the polymerase chain reaction conversion. Among the most common symptoms, 30 (73.8%) convalescents had an increase in body temperature to 38C, 32 (83.3%) had asthenia, 21 (59.5%) had cough, 29 (73.8%) had perversion or loss of sense of smell, pain, and throat discomfort. The duration of symptoms varied from 34 days to 34 weeks. Within a month after the end of the acute disease period, 8 (20%) patients had a decrease in working capacity, 13 (33%) had difficulty breathing, 9 (22%) had a cough, and 4 (10%) had pain and sore throat. During severe acute respiratory syndrome 2 infection, the virus activates the innate and adaptive immunity, resulting in the formation of specific class G immunoglobulins to the pathogens. After leveling the clinical manifestations, class G immunoglobulins were detected in the majority of convalescents (79%90%) during the first 6 months, starting from day 14 from disease onset with a predominantly high ( 10 conl. units) positivity coefficient. Moreover, this pattern occurred in both men and women; however, in some studies, the levels of the positivity coefficient of class G immunoglobulins began to decrease by the fifth month of follow-up and sometimes at an earlier time (2 months). Perhaps, this is due to the different functional activities of the immune system of each convalescent, infecting dose of the pathogen, and peculiarities of its interaction with the macroorganism and its immune system. Nevertheless, the class G immunoglobulins identified in the study do not yet indicate the probability of reinfection of convalescents with the same pathogen. The protective titer of antibodies has yet to be investigated further.
- Open Access
- 15 October 2022
- Published by ECO-Vector LLC in Bulletin of the Russian Military Medical Academy
- Vol. 24 (3) , 467-474
Justification of tactical and technical sample requirements mass immunoprophylaxis dangerous infectious diseases in the Armed Forces of the Russian Federation
The results of the analysis of the current state of creating a technical means of mass immunoprophylaxis for dangerous infectious diseases are presented, including the technical level and trends in the development of developments on this problem in the Russian Federation and abroad. It was noted that in emergency situations of a biological nature, a vaccination campaign should be carried out in a short time with maximum personnel vaccination coverage, which is a massive undertaking. These requirements can be only be met with the use of mass vaccination in the form of needle-free, inhalation (aerosol) and oral vaccine administration methods. The wide use of these methods is constrained by a meager range of domestic oral vaccines, as well as the lack of technical means of mass immunization (aerosol generators, needleless injectors). This article shows that the needleless injector NI-30 (Russia) is the most appropriate for mass vaccination, in terms of technical level and operational characteristics. However, it cannot be recognized as fully meeting modern requirements due to a number of negative aspects, such as the rather large overall injector dimensions creating a large amount of obsolete structural materials. Thus, it is necessary to take into account the features of the available methods of vaccine administration when assessing the prospects for mass immunization, and it is necessary to substantiate the tactical and technical requirements for new generation samples in order to develop the technical means of mass immunization. Therefore, the development and introduction into practice of high-performance methods of mass immunization and the technical means for their implementation continues to be an urgent task.
- 15 October 2022
- Published by ECO-Vector LLC in Bulletin of the Russian Military Medical Academy
- Vol. 24 (3) , 467-474
Open AccessJustification of tactical and technical sample requirements mass immunoprophylaxis dangerous infectious diseases in the Armed Forces of the Russian Federation
The results of the analysis of the current state of creating a technical means of mass immunoprophylaxis for dangerous infectious diseases are presented, including the technical level and trends in the development of developments on this problem in the Russian Federation and abroad. It was noted that in emergency situations of a biological nature, a vaccination campaign should be carried out in a short time with maximum personnel vaccination coverage, which is a massive undertaking. These requirements can be only be met with the use of mass vaccination in the form of needle-free, inhalation (aerosol) and oral vaccine administration methods. The wide use of these methods is constrained by a meager range of domestic oral vaccines, as well as the lack of technical means of mass immunization (aerosol generators, needleless injectors). This article shows that the needleless injector NI-30 (Russia) is the most appropriate for mass vaccination, in terms of technical level and operational characteristics. However, it cannot be recognized as fully meeting modern requirements due to a number of negative aspects, such as the rather large overall injector dimensions creating a large amount of obsolete structural materials. Thus, it is necessary to take into account the features of the available methods of vaccine administration when assessing the prospects for mass immunization, and it is necessary to substantiate the tactical and technical requirements for new generation samples in order to develop the technical means of mass immunization. Therefore, the development and introduction into practice of high-performance methods of mass immunization and the technical means for their implementation continues to be an urgent task.
- Open Access
- 20 April 2022
- Published by ECO-Vector LLC in Bulletin of the Russian Military Medical Academy
- Vol. 24 (1) , 135-142
Alphaviruses: a modern view on the problem
At present, infectious diseases of alphaviral etiology remain relevant. The study examined the characteristics of alphaviruses, including the present knowledge of the structure and replication of the virion; prevalence of epidemiologically significant species and potential distribution areas of some alphaviruses; pathogenesis and clinical presentation of causative diseases, diagnosis, prevention, and treatment; and their possible use as pathogenic biological agents. Sixteen strains of alphaviruses are hazardous to human health, and some of them can disrupt human activities. Areas with alphaviruses are characterized by specific ecological conditions, presence of vectors, and susceptible hosts. Alphaviruses are predominantly distributed in equatorial and subequatorial belts. Some alphaviruses have been reported in the Russian Federation. The natural foci of alphaviruses are reportedly altered because of the expansion of their existing localizations, including the Russian territory. To predict the occurrence of alphavirus outbreaks, it is necessary to monitor pathogenic populations for mutations that can significantly increase their pathogenicity and virulence. Most alphaviruses, including those registered in Russia, do not have specific products for diagnostics, prevention, and treatment. Meanwhile, alphaviral diseases have great militaryepidemiological significance, as they can cause natural focal morbidity in certain regions of the world and injury to the civilian population and service personnel following their use as pathogenic biological agents.
- 20 April 2022
- Published by ECO-Vector LLC in Bulletin of the Russian Military Medical Academy
- Vol. 24 (1) , 135-142
Open AccessAlphaviruses: a modern view on the problem
At present, infectious diseases of alphaviral etiology remain relevant. The study examined the characteristics of alphaviruses, including the present knowledge of the structure and replication of the virion; prevalence of epidemiologically significant species and potential distribution areas of some alphaviruses; pathogenesis and clinical presentation of causative diseases, diagnosis, prevention, and treatment; and their possible use as pathogenic biological agents. Sixteen strains of alphaviruses are hazardous to human health, and some of them can disrupt human activities. Areas with alphaviruses are characterized by specific ecological conditions, presence of vectors, and susceptible hosts. Alphaviruses are predominantly distributed in equatorial and subequatorial belts. Some alphaviruses have been reported in the Russian Federation. The natural foci of alphaviruses are reportedly altered because of the expansion of their existing localizations, including the Russian territory. To predict the occurrence of alphavirus outbreaks, it is necessary to monitor pathogenic populations for mutations that can significantly increase their pathogenicity and virulence. Most alphaviruses, including those registered in Russia, do not have specific products for diagnostics, prevention, and treatment. Meanwhile, alphaviral diseases have great militaryepidemiological significance, as they can cause natural focal morbidity in certain regions of the world and injury to the civilian population and service personnel following their use as pathogenic biological agents.
- Open Access
- 20 April 2022
- Published by ECO-Vector LLC in Bulletin of the Russian Military Medical Academy
- Vol. 24 (1) , 165-177
Inflammatory response and its correction in forming a host response to exposure to adverse environmental factors
This study systematically review knowledge about the mechanisms of formation of an inflammatory reaction under the influence of biological, physical, and chemical factors, their similarities and differences, and possible methods of pharmacological correction of pathological conditions associated with excessive activation. The effect of adverse environmental factors, such as biological, physical, and chemical factors, causes a systemic response, which is aimed at maintaining homeostasis and is caused, among other things, by a coordinated reaction of the immune system. Phlogogenic agents result in the activation and regulation of the inflammatory response, which is formed by cellular and humoral components of innate immunity. The activation of innate immunity is characterized by a rapid host response, which diminishes following the elimination of foreign invaders, endogenous killer cells, and neogenesis. Depending on the nature of the active factors (biopathogens, allergens, toxins, ionizing radiation, etc.), the mechanisms of immune response arousal have unique features mainly originating from the differences in the recognition of specific molecular patterns and danger signals by different receptors. However, inflammatory mediators and inflammatory response patterns at the systemic level are largely similar even under widely different triggers. Inflammation, having evolved as an adaptive reaction directed at the immune response, can lead to the development of chronic inflammation and autoimmune diseases due to a mismatch in mechanisms of its control. A failure in the regulation of the inflammatory process is the excessive activation of the immune system, which leads to the cytokine release syndrome (hypercytokinemia, or cytokine storm) and can cause self-damage (destruction) of tissues, multiple-organ failure, sepsis, and even death. Modern advances in the study of the pathogenetic bases of the inflammatory response are suggested, such as pharmacological correction using pattern recognition receptor antagonists, pro-inflammatory cytokine inhibitors, or blocking of key control genes or signaling pathways.
- 20 April 2022
- Published by ECO-Vector LLC in Bulletin of the Russian Military Medical Academy
- Vol. 24 (1) , 165-177
Open AccessInflammatory response and its correction in forming a host response to exposure to adverse environmental factors
This study systematically review knowledge about the mechanisms of formation of an inflammatory reaction under the influence of biological, physical, and chemical factors, their similarities and differences, and possible methods of pharmacological correction of pathological conditions associated with excessive activation. The effect of adverse environmental factors, such as biological, physical, and chemical factors, causes a systemic response, which is aimed at maintaining homeostasis and is caused, among other things, by a coordinated reaction of the immune system. Phlogogenic agents result in the activation and regulation of the inflammatory response, which is formed by cellular and humoral components of innate immunity. The activation of innate immunity is characterized by a rapid host response, which diminishes following the elimination of foreign invaders, endogenous killer cells, and neogenesis. Depending on the nature of the active factors (biopathogens, allergens, toxins, ionizing radiation, etc.), the mechanisms of immune response arousal have unique features mainly originating from the differences in the recognition of specific molecular patterns and danger signals by different receptors. However, inflammatory mediators and inflammatory response patterns at the systemic level are largely similar even under widely different triggers. Inflammation, having evolved as an adaptive reaction directed at the immune response, can lead to the development of chronic inflammation and autoimmune diseases due to a mismatch in mechanisms of its control. A failure in the regulation of the inflammatory process is the excessive activation of the immune system, which leads to the cytokine release syndrome (hypercytokinemia, or cytokine storm) and can cause self-damage (destruction) of tissues, multiple-organ failure, sepsis, and even death. Modern advances in the study of the pathogenetic bases of the inflammatory response are suggested, such as pharmacological correction using pattern recognition receptor antagonists, pro-inflammatory cytokine inhibitors, or blocking of key control genes or signaling pathways.
- Open Access
- 15 December 2021
- Published by ECO-Vector LLC in Bulletin of the Russian Military Medical Academy
- Vol. 23 (4) , 247-256
Application aspects of medications for inhalation at the prehospital stage of medical evacuation
This study aimed to determine the aspects of inhalation application of drugs as medical means of protection against lesions by factors of radiation, chemical, and biological nature at the prehospital stage of medical evacuation. Advantages of inhalation administration of drugs and use of individual inhalers of portable type over parenteral and oral administration methods are described. The existing drugs that are most suitable for inhalation at the prehospital stage of medical evacuation include emergency prevention and treatment of toxic pulmonary edema, analgesics, antiradiation, drugs for arresting radiation primary reaction, agents for accelerated radionuclides elimination, and antibacterial and antiviral agents. This list is conditioned by the rapid achievement of the protective effect of the drug during inhalation, both due to the local action in the area of the entrance gate of the intake of damaging agents and the accelerated absorption and systemic action on target organs. This study presents data on existing and promising inhalation drugs (antidotes for warfare agents, recombinant forms of acetyl- and butyrylcholinesterase) and technical means of their delivery (a metered aerosol inhaler, a metered dry powder inhaler) in the Armed Forces of the European North Atlantic Treaty Organization bloc and the United States for the prevention and treatment of damage e to chemical agents, as well as the prospects of radiomitigator usage (granulocyte-macrophage colony-stimulating factor) by inhalations for acute radiation syndrome treatment and inhalation of complexones of radioactive isotopes. The prospects of inhalation in combination with bronchodilators in the development of acute respiratory failure and toxic pulmonary edema on the background of poisoning with the use of a metered-dose powder inhaler are described. The introduction and use of a metered-dose dry powder inhaler at the prehospital stage of medical evacuation determines the need for its development, taking into account the specifics of the drug usage, as well as the need to unify the dosage form of drugs in combination with one type of inhaler (single-dose or multi-dose).
- 15 December 2021
- Published by ECO-Vector LLC in Bulletin of the Russian Military Medical Academy
- Vol. 23 (4) , 247-256
Open AccessApplication aspects of medications for inhalation at the prehospital stage of medical evacuation
This study aimed to determine the aspects of inhalation application of drugs as medical means of protection against lesions by factors of radiation, chemical, and biological nature at the prehospital stage of medical evacuation. Advantages of inhalation administration of drugs and use of individual inhalers of portable type over parenteral and oral administration methods are described. The existing drugs that are most suitable for inhalation at the prehospital stage of medical evacuation include emergency prevention and treatment of toxic pulmonary edema, analgesics, antiradiation, drugs for arresting radiation primary reaction, agents for accelerated radionuclides elimination, and antibacterial and antiviral agents. This list is conditioned by the rapid achievement of the protective effect of the drug during inhalation, both due to the local action in the area of the entrance gate of the intake of damaging agents and the accelerated absorption and systemic action on target organs. This study presents data on existing and promising inhalation drugs (antidotes for warfare agents, recombinant forms of acetyl- and butyrylcholinesterase) and technical means of their delivery (a metered aerosol inhaler, a metered dry powder inhaler) in the Armed Forces of the European North Atlantic Treaty Organization bloc and the United States for the prevention and treatment of damage e to chemical agents, as well as the prospects of radiomitigator usage (granulocyte-macrophage colony-stimulating factor) by inhalations for acute radiation syndrome treatment and inhalation of complexones of radioactive isotopes. The prospects of inhalation in combination with bronchodilators in the development of acute respiratory failure and toxic pulmonary edema on the background of poisoning with the use of a metered-dose powder inhaler are described. The introduction and use of a metered-dose dry powder inhaler at the prehospital stage of medical evacuation determines the need for its development, taking into account the specifics of the drug usage, as well as the need to unify the dosage form of drugs in combination with one type of inhaler (single-dose or multi-dose).
- 30 August 2021
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 66 (5-6) , 58-71
Meta-analysis of randomized clinical trials of Riamilovir efficacy in etiotropic therapy of influenza
The aim of the study was to carry out a meta-analysis of randomized clinical trials in order to combine the results of clinical trials on Triazavirin® (Riamilovir) efficacy in etiotropic therapy of influenza.Materials and methods. The analysis was carried out in accordance with the PRISMA principles regarding the quality of information presentation on the results of systematic reviews and meta-analyzes of works assessing medical interventions. The study included 471 patients with a confirmed diagnosis of influenza (with laboratory confirmed presence of influenza virus antigens).Results. The conducted meta-analysis showed that the use of Triazavirin® (Riamilovir) has a statistically significant effect on the severity of clinical symptoms in patients with influenza, therefore Riamilovir can be used in the initial therapy of adult patients with influenza.Conclusion. Clinical studies have shown that the use of Triazavirin® (Riamilovir) is effective both in the initial and late stages of the disease, and therefore Riamilovir can be used in the treatment of adult patients with respiratory diseases of viral etiology, in particular, those diagnosed with influenza. The meta-analysis of the collected data showed that therapy with Triazavirin® (Riamilovir) has statistically significant advantages in various aspects both in comparison with the placebo group and with the Tamiflu® (Oseltamivir) group.
- 30 August 2021
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 66 (5-6) , 58-71
Meta-analysis of randomized clinical trials of Riamilovir efficacy in etiotropic therapy of influenza
The aim of the study was to carry out a meta-analysis of randomized clinical trials in order to combine the results of clinical trials on Triazavirin® (Riamilovir) efficacy in etiotropic therapy of influenza.Materials and methods. The analysis was carried out in accordance with the PRISMA principles regarding the quality of information presentation on the results of systematic reviews and meta-analyzes of works assessing medical interventions. The study included 471 patients with a confirmed diagnosis of influenza (with laboratory confirmed presence of influenza virus antigens).Results. The conducted meta-analysis showed that the use of Triazavirin® (Riamilovir) has a statistically significant effect on the severity of clinical symptoms in patients with influenza, therefore Riamilovir can be used in the initial therapy of adult patients with influenza.Conclusion. Clinical studies have shown that the use of Triazavirin® (Riamilovir) is effective both in the initial and late stages of the disease, and therefore Riamilovir can be used in the treatment of adult patients with respiratory diseases of viral etiology, in particular, those diagnosed with influenza. The meta-analysis of the collected data showed that therapy with Triazavirin® (Riamilovir) has statistically significant advantages in various aspects both in comparison with the placebo group and with the Tamiflu® (Oseltamivir) group.
- 30 August 2021
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 66 (5-6) , 48-57
Meta-analysis of randomized controlled clinical trials of Riamilovir efficacy in the etiotropic therapy of acute respiratory viral infection
The aimof the study was to carry out meta-analysis of randomized controlled trials in order to combine the results of clinical trials on Triazavirin®(Riamilovir) efficacy in the etiotropic therapy of acute respiratory viral infection.Materials and methods.The studies included 435 patients with a confirmed diagnosis of acute respiratory viral infection or ARVI (with laboratory confirmed absence of influenza virus antigens). The research was carried out in 27 centers. In studies, patients were divided into 3 groups in a 1:1:1 ratio (a total of 145 people per group). Each study included a group taking 100 mg of the medication 5 times a day, a group taking 250 mg of the medication 3 times a day and a placebo 2 times a day, as well as a group taking a placebo 5 times a day. The analysis was carried out in accordance with the PRISMA principles regarding the quality of information presentation on the results of systematic reviews and meta-analyzes of works evaluating the effects of medical interventions.Results. The conducted meta-analysis showed that the use of Triazavirin®(Riamilovir) has a statistically significantly effects on the severity of clinical symptoms in patients with ARVI. The performed meta-analysis confirmed reliable associations between the use of Triazavirin®(Riamilovir) in both doses and the chance of a persistent improvement in clinical symptoms on the 5thday of therapy. The meta-analysis also confirmed the statistical significance of the clinical effects of Riamilovir by such indicators as the area under the curve «point on the scale showing the severity of the condition in a patient with ARVI in relation to time», the proportion of patients with complete alleviation of all symptoms by the end of the 5th day from the start of therapy.Conclusion.The clinical trials proved that the use of Triazavirin®(Riamilovir) is effective both in the initial and in the late stages of the disease, therefore, the drug can be used in the initial therapy of adult patients with respiratory diseases of viral etiology.
- 30 August 2021
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 66 (5-6) , 48-57
Meta-analysis of randomized controlled clinical trials of Riamilovir efficacy in the etiotropic therapy of acute respiratory viral infection
The aimof the study was to carry out meta-analysis of randomized controlled trials in order to combine the results of clinical trials on Triazavirin®(Riamilovir) efficacy in the etiotropic therapy of acute respiratory viral infection.Materials and methods.The studies included 435 patients with a confirmed diagnosis of acute respiratory viral infection or ARVI (with laboratory confirmed absence of influenza virus antigens). The research was carried out in 27 centers. In studies, patients were divided into 3 groups in a 1:1:1 ratio (a total of 145 people per group). Each study included a group taking 100 mg of the medication 5 times a day, a group taking 250 mg of the medication 3 times a day and a placebo 2 times a day, as well as a group taking a placebo 5 times a day. The analysis was carried out in accordance with the PRISMA principles regarding the quality of information presentation on the results of systematic reviews and meta-analyzes of works evaluating the effects of medical interventions.Results. The conducted meta-analysis showed that the use of Triazavirin®(Riamilovir) has a statistically significantly effects on the severity of clinical symptoms in patients with ARVI. The performed meta-analysis confirmed reliable associations between the use of Triazavirin®(Riamilovir) in both doses and the chance of a persistent improvement in clinical symptoms on the 5thday of therapy. The meta-analysis also confirmed the statistical significance of the clinical effects of Riamilovir by such indicators as the area under the curve «point on the scale showing the severity of the condition in a patient with ARVI in relation to time», the proportion of patients with complete alleviation of all symptoms by the end of the 5th day from the start of therapy.Conclusion.The clinical trials proved that the use of Triazavirin®(Riamilovir) is effective both in the initial and in the late stages of the disease, therefore, the drug can be used in the initial therapy of adult patients with respiratory diseases of viral etiology.
- 1 January 2014
- Published by Akademizdatcenter Nauka in Генетика
- Vol. 50 (3) , 273-281
Мутацияpetiteподавляет индукцию синтеза белка теплового шока (Hsp104)Saccharomyces cerevisiaeв стационарной фазе роста
- 1 January 2014
- Published by Akademizdatcenter Nauka in Генетика
- Vol. 50 (3) , 273-281
Мутацияpetiteподавляет индукцию синтеза белка теплового шока (Hsp104)Saccharomyces cerevisiaeв стационарной фазе роста